氟轻松巩膜固定植入物治疗虹膜-晶状体隔破坏合并人工晶状体眼黄斑囊样水肿的长期疗效(MEFISTO)
这项前瞻性超说明书介入临床试验在10只虹膜-晶状体隔破坏合并人工晶状体眼黄斑囊样水肿(PCME)眼中行氟轻松环锚定巩膜固定植入,评估2年疗效与安全性。结果显示最佳矫正视力在1个月时显著改善至0.57±0.38 logMAR(P=0.003),黄斑中心厚度1个月时从601.6±235.5 µm降至449.1±128.9 µm(下降22%),24个月随访期内解剖与功能结果良好,安全性可接受。
要点
- 10只虹膜-晶状体隔破坏合并PCME眼行氟轻松植入物巩膜固定,随访24个月。
- 最佳矫正视力1个月时显著改善至0.57±0.38 logMAR(P=0.003)。
- 黄斑中心厚度1个月时从601.6±235.5 µm降至449.1±128.9 µm,下降22%。
核心结论
- 在虹膜-晶状体隔破坏眼中,巩膜固定氟轻松植入物治疗难治性人工晶状体眼黄斑囊样水肿,在24个月内提供良好的解剖与功能结果,安全性可接受,此类PCME原本难以治疗且常被搁置不治。
研究设计与样本
- 前瞻性超说明书介入临床试验,共10只眼行氟轻松植入物巩膜固定,随访24个月,主要结局为最佳矫正视力、黄斑中心厚度变化及手术总体安全性。
主要发现
- 最佳矫正视力在1个月时显著改善至0.57±0.38 logMAR(Snellen 20/80,范围0-1.30)(P=0.003)。
- 黄斑中心厚度1个月时从601.6±235.5 µm降至449.1±128.9 µm,下降22%。
- 1例患者因眼压升高于第7个月取出植入物;1例眼球破裂后患者于第4个月发生视网膜再脱离。
临床怎么用
- 作者在结论中认为,对虹膜-晶状体隔破坏合并难治性人工晶状体眼黄斑囊样水肿、原本难以治疗且常被搁置不治的眼,巩膜固定氟轻松植入物可提供良好的解剖与功能结果,安全性可接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of our prospective off-label, interventional clinical trial was to evaluate the efficacy and safety of the fluocinolone-loop-anchoring technique over two years in eyes with iris-lens diaphragm disruption and pseudophakic cystoid macular edema. METHODS: In 10 eyes, scleral fixation of fluocinolone implant was performed. Main outcome measures were the development of best-corrected visual acuity (BCVA), central retinal thickness over 24 months, and general safety of the procedure. RESULTS: A significant improvement to 0.57 ± 0.38 log MAR (Snellen 20/80) (range 0-1.30) was observed (P = 0.003) at 1 month. Further improvement to 0.45 ± 036 log MAR (Snellen 20/60) was observed until month 18 (P = 0.081). Mean central retinal thickness decreased by 22% from 601.6 ± 235.5 µm to 449.1 ± 128.9 µm at 1 month. In one patient, the implant has to be removed at Month 7 because of elevated intraocular pressure and one patient after globe rupture had a retinal redetachment at Month 4. CONCLUSION: In this study, we showed that the treatment of recalcitrant pseudophakic cystoid macular edema with scleral fixated fluocinolone implant in eyes with disruption of the iris-lens diaphragm provides good anatomical and functional results with a reasonable safety profile over 24 months in eyes where pseudophakic cystoid macular edema is otherwise difficult to treat and often left untreated.
引用
- Herold TR, Vounotrypidis E, Liegl R, et al. LONG-TERM EFFICACY OF FLUOCINOLONE IN EYES WITH IRIS-LENS DIAPHRAGM DISRUPTION AND PCME WITH MEDICATION FIXED IN THE SCLERA (MEFISTO). Retina. 2022. PMID: 35321998. doi:10.1097/IAE.0000000000003472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。